Delos Capital

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.

Viron is a biopharmaceutical company that uses breakthrough discovery and novel technologies to identify and develop patent-pending high-value therapies for currently unarguable porosome protein and lipid targets in cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Breakthroughs in genomics and gene editing technologies, stem cell biology, patient-derived organoids, cryo-electron microscopy, synthetic biology, small molecule screening, and image analysis using AI machine learning and high-throughput screening have transformed the drug discovery landscape.

Viron is a biopharmaceutical company that uses breakthrough discovery and novel technologies to identify and develop patent-pending high-value therapies for currently unarguable porosome protein and lipid targets in cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Breakthroughs in genomics and gene editing technologies, stem cell biology, patient-derived organoids, cryo-electron microscopy, synthetic biology, small molecule screening, and image analysis using AI machine learning and high-throughput screening have transformed the drug discovery landscape.

Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery.

Phanes Therapeutics is a biotech company focused on discovery and development of therapeutics for solid tumors and eye diseases. Their extensive experience and deep scientific knowledge strongly position us to discover and advance robust therapeutic molecules. Through scientific innovation, we deliver better treatment options for patients. Their mission is to relentlessly seek scientific and technological solutions to improve the lives of patients globally.

Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.

Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.

Rejoni develops solutions designed to minimize the short and long-term risks associated with gynecological procedures. It is working on developing solutions that minimize both acute and chronic risks associated with gynecologic procedures by providing women’s health-centered technologies that help women to achieve the life they want both now and in the future.

Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery.

Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.

Curamir is a Woburn, MA-based biotechnology company launched and incubated by Delos Capital with an initial academic licensing from SUNY. Through its proprietary miRNA engineering platform and insights into cancer biology, Curamir develops miRNA-based cancer therapeutics with enhanced safety, potency and stability. Its novel approach addresses current challenges associated with both chemoresistance in cancer and effective systemic delivery of miRNA mimics.

Viron is a biopharmaceutical company that uses breakthrough discovery and novel technologies to identify and develop patent-pending high-value therapies for currently unarguable porosome protein and lipid targets in cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Breakthroughs in genomics and gene editing technologies, stem cell biology, patient-derived organoids, cryo-electron microscopy, synthetic biology, small molecule screening, and image analysis using AI machine learning and high-throughput screening have transformed the drug discovery landscape.

Barricaid develops a bone-anchored implant that reduces the incidence of reherniation and reoperation in patients with large annular defects. It is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect. The anchor component is comprised of titanium alloy that is placed into either the caudal or cranial-adjacent vertebral body to secure the device in position.

Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.

HOP Energy is an energy company, that provides residential and commercial energy services throughout the Northeast. Its services to residential customers include heating oils; propane fuel and tanks; selling and installing a range of heating and cooling equipment; 24-hour service; and comprehensive service contracts for heating, air conditioning, and other important equipment, such as water heaters and humidifiers.

US Fitness Products provides fitness and gym equipment services to retail and commercial clients. Their services include home gym design, consumer financing, repair, preventative maintenance, commercial fitness solutions, commercial leasing, installation, and relocation.

Sage Metals Ltd. is a manufacturer of specialty metal products serving the North American electrical, power utility, industrial, and drainage end markets. The Company was founded over 30 years ago.

Liposeuticals, Inc. is a specialty pharmaceuticals firm focused on the development of next-generation proprietary formulations of sterile injectable drugs, principally aimed at the domains of anesthesiology, oncology and infectious disease. The firm has developed a revolutionary approach to the formulation of non-water-soluble drugs, which enables the creation of products with greater stability, superior shelf life, improved ease of manufacturing and enhanced safety. The firm's pipeline is specifically geared towards development via the 505(b)(2) pathway at the United States Food and Drug Administration (FDA), which substantially expedites the development, review and approval timeline. Liposeuticals also seeks to extend the commercial window of its products through the generation of novel intellectual property and other regulatory exclusivity available via the Hatch-Waxman Act.

Barricaid develops a bone-anchored implant that reduces the incidence of reherniation and reoperation in patients with large annular defects. It is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect. The anchor component is comprised of titanium alloy that is placed into either the caudal or cranial-adjacent vertebral body to secure the device in position.

Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra has a novel β-lactamase inhibitor in Phase 2 clinical development. By inhibiting β-lactamases Allecra’s new medicine directly tackles emerging resistance mechanisms of certain hard-to-treat bacteria. These resistance mechanisms are often found in hospital-acquired Gram-negative bacterial infections, and are of particular concern to doctors, healthcare providers, to patients and their families and to governments around the world. Allecra Therapeutics is situated in the BioValley Life Sciences region in the Upper Rhein valley whichencompasses northwest Switzerland, southwestern Germany and the Alsace region of France

BAROnova, founded in 2006 and based in Goleta, CA, is a clinical-stage medical-device company focused on developing non-surgical non-pharmacologic devices to induce weight loss.

Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.

Atia Medical is a medical device company focusing on advancing eye care through the innovation of ophthalmic devices, diagnostics, and pharmaceuticals. The company is focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer healthier lives. They improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens. Atia Vision modular intraocular lens technology features an accommodating base responsive to the ciliary muscles, simulating the natural mechanism of the eye and fixed lens element that allows for subsequent refractive correction. The company's unique technology enables natural accommodation, utilizing the ciliary muscles of the eye and providing for subsequent refractive correction, to restore the full range of functional vision for cataract patients. Atria Vision was founded in 2012 and is headquartered in Campbell, California, United States.

Since its founding in 1985, FCA has been supplying a broad range of highly customized, heavy-duty industrial packaging products and services to many of the world’s leading OEM’s in several industries. Whether you need wood, steel, corrugated or hybrid packaging; expendable, reusable or returnable products, FCA provides comprehensive solutions that bring total value to your organization for your packaging peace of mind. FCA’s custom products include custom engineered skids, crates, pallets, boxes, collapsible boxes and other unique packaging solutions that protect over a billion dollars of valuable customer inventory. FCA also supports its packaging products with an array of value-added services including design, testing manufacturing, container management and tracking, recycle management and repair/refurbishment.

Innovative Chemical Products (the ICP Group) is a specialty platform company in the coatings, adhesives, sealants, and elastomers (CASE) markets. ICP Group focuses on accelerating organic growth through building world-class organizations and technologies, and then augmenting it with strategic acquisitions. Current ICP Group leadership includes members of the former Quest Specialty Chemicals platform, which was the 12th largest specialty coatings platform in the United States before its successful sale in 2015. Working with and leveraging Audax Group’s experience in building companies through acquisition, including within the specialty chemicals sector, we have built a specialty formulated products platform, with our leading brands, scalable operations, and talented leadership and employees. Their current partners continue to operate as standalone business units of the combined platform. They are laser-focused on their target markets, partnering with their customers through their emphasis on service, quality and innovation. The added strength of the ICP Group relationship brings benefits through raw material purchasing, technological collaboration, and shared service.